At a glance
ClinicalIndex Comparison RecordN/ACompleted· 106 enrolled
Drug / intervention
SPP100drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1
In Brief
An observational study evaluating SPP100 for Hypertension. Completed, enrolled 106 participants across 25 sites in 7 countries.
Detailed Summary
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesGuatemala, Hungary, Poland, Puerto Rico, Slovakia, Turkey (Türkiye), United States
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2011
Enrollment StartAug 2011
Primary CompletionAug 2017
TodayJul 2026
First PostedAug 19, 2011
Enrollment StartAug 19, 2011
Primary CompletionAug 3, 2017
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 14.9 years ago
Interventions
SPP100drug